AZ-D516NC00001-TROPION-LUNG14
Phase III
OPEN TO ACCRUAL *
A Phase III, Open-Label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-Line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
IIT-THOMPSON-RADIANCE-LUNG-X
Phase II
OPEN TO ACCRUAL
Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-Small Cell Lung Cancers (RadiaNCe Lung X)
LILLY-J3M-MC-JZQH
Phase III
OPEN TO ACCRUAL *
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
NRG-LU008
Phase III
OPEN TO ACCRUAL
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
TAIHO-TAS6417-201
Phase II
OPEN TO ACCRUAL
An Open-Label, Phase 2b, Global Multi-Center Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertions and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations